cloudfront

Report Detail



Pharmaceuticals & HealthcareRetinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Pipeline Review, H2 2018

  • RnM2315586
  • |
  • 7 August, 2018
  • |
  • Global
  • |
  • 75 pages
  • |
  • Global Markets Direct
  • |
  • Pharmaceuticals & Healthcare

Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Pipeline Review, H2 2018

Table of Contents

    List of Tables

      List of Figures

        Introduction

          Global Markets Direct Report Coverage

            Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Overview

              Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Therapeutics Development

                Products under Development by Stage of Development

                  Products under Development by Therapy Area

                    Products under Development by Indication

                      Products under Development by Companies

                        Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Therapeutics Assessment

                          Assessment by Mechanism of Action

                            Assessment by Route of Administration

                              Assessment by Molecule Type

                                Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Companies Involved in Therapeutics Development

                                  3SBio Inc

                                    Bausch Health Companies Inc

                                      Boehringer Ingelheim GmbH

                                        Clementia Pharmaceuticals Inc

                                          Galderma SA

                                            Lee's Pharmaceutical Holdings Ltd

                                              Phosphagenics Ltd

                                                Promius Pharma LLC

                                                  Sol-Gel Technologies Ltd

                                                    Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Drug Profiles

                                                      (adapalene + benzoyl peroxide + clindamycin phosphate) - Drug Profile

                                                        Product Description

                                                          Mechanism Of Action

                                                            R&D Progress

                                                              (adapalene + clindamycin hydrochloride) - Drug Profile

                                                                Product Description

                                                                  Mechanism Of Action

                                                                    R&D Progress

                                                                      (benzoyl peroxide + tretinoin) - Drug Profile

                                                                        Product Description

                                                                          Mechanism Of Action

                                                                            R&D Progress

                                                                              (benzoyl peroxide + tretinoin) - Drug Profile

                                                                                Product Description

                                                                                  Mechanism Of Action

                                                                                    R&D Progress

                                                                                      (clindamycin phosphate + tretinoin) - Drug Profile

                                                                                        Product Description

                                                                                          Mechanism Of Action

                                                                                            R&D Progress

                                                                                              (halobetasol propionate + tazarotene) - Drug Profile

                                                                                                Product Description

                                                                                                  Mechanism Of Action

                                                                                                    R&D Progress

                                                                                                      (TPX-6001 + tretinoin) - Drug Profile

                                                                                                        Product Description

                                                                                                          Mechanism Of Action

                                                                                                            R&D Progress

                                                                                                              alitretinoin - Drug Profile

                                                                                                                Product Description

                                                                                                                  Mechanism Of Action

                                                                                                                    R&D Progress

                                                                                                                      bexarotene + CD1530 - Drug Profile

                                                                                                                        Product Description

                                                                                                                          Mechanism Of Action

                                                                                                                            R&D Progress

                                                                                                                              palovarotene - Drug Profile

                                                                                                                                Product Description

                                                                                                                                  Mechanism Of Action

                                                                                                                                    R&D Progress

                                                                                                                                      Small Molecule to Antagonize ROR-Gamma for Autoimmune and Allergic Disorders - Drug Profile

                                                                                                                                        Product Description

                                                                                                                                          Mechanism Of Action

                                                                                                                                            R&D Progress

                                                                                                                                              Small Molecules 1 to Agonize Retinoic Acid Receptor Gamma for Musculoskeletal Disorders - Drug Profile

                                                                                                                                                Product Description

                                                                                                                                                  Mechanism Of Action

                                                                                                                                                    R&D Progress

                                                                                                                                                      Small Molecules to Agonize RARG for Fibrosis - Drug Profile

                                                                                                                                                        Product Description

                                                                                                                                                          Mechanism Of Action

                                                                                                                                                            R&D Progress

                                                                                                                                                              Small Molecules to Agonize Retinoic Acid Receptor Gamma for Musculoskeletal Disorders - Drug Profile

                                                                                                                                                                Product Description

                                                                                                                                                                  Mechanism Of Action

                                                                                                                                                                    R&D Progress

                                                                                                                                                                      tazarotene - Drug Profile

                                                                                                                                                                        Product Description

                                                                                                                                                                          Mechanism Of Action

                                                                                                                                                                            R&D Progress

                                                                                                                                                                              tazarotene - Drug Profile

                                                                                                                                                                                Product Description

                                                                                                                                                                                  Mechanism Of Action

                                                                                                                                                                                    R&D Progress

                                                                                                                                                                                      tretinoin - Drug Profile

                                                                                                                                                                                        Product Description

                                                                                                                                                                                          Mechanism Of Action

                                                                                                                                                                                            R&D Progress

                                                                                                                                                                                              tretinoin - Drug Profile

                                                                                                                                                                                                Product Description

                                                                                                                                                                                                  Mechanism Of Action

                                                                                                                                                                                                    R&D Progress

                                                                                                                                                                                                      tretinoin - Drug Profile

                                                                                                                                                                                                        Product Description

                                                                                                                                                                                                          Mechanism Of Action

                                                                                                                                                                                                            R&D Progress

                                                                                                                                                                                                              trifarotene - Drug Profile

                                                                                                                                                                                                                Product Description

                                                                                                                                                                                                                  Mechanism Of Action

                                                                                                                                                                                                                    R&D Progress

                                                                                                                                                                                                                      vitamin A palmitate - Drug Profile

                                                                                                                                                                                                                        Product Description

                                                                                                                                                                                                                          Mechanism Of Action

                                                                                                                                                                                                                            R&D Progress

                                                                                                                                                                                                                              vitamin A palmitate - Drug Profile

                                                                                                                                                                                                                                Product Description

                                                                                                                                                                                                                                  Mechanism Of Action

                                                                                                                                                                                                                                    R&D Progress

                                                                                                                                                                                                                                      Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Dormant Products

                                                                                                                                                                                                                                        Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Discontinued Products

                                                                                                                                                                                                                                          Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Product Development Milestones

                                                                                                                                                                                                                                            Featured News & Press Releases

                                                                                                                                                                                                                                              Jun 18, 2018: FDA declines to approve Valeant’s plaque psoriasis lotion

                                                                                                                                                                                                                                                Jun 18, 2018: FDA Issues Complete Response Letter For DUOBRII (Halobetasol Propionate and Tazarotene) Lotion

                                                                                                                                                                                                                                                  May 23, 2018: Clementia Reports Positive Phase 2 Part B Data Showing Treatment with Palovarotene Significantly Reduces New Bone Growth in Patients with FOP

                                                                                                                                                                                                                                                    Apr 20, 2018: Clementia Initiates Phase 2 MO-Ped Trial for Palovarotene in Patients with Multiple Osteochondromas

                                                                                                                                                                                                                                                      Apr 09, 2018: Ortho Dermatologics Announces Publication of Pivotal Efficacy And Safety Data For Psoriasis Treatment DUOBRII In The Journal of the American Academy of Dermatology

                                                                                                                                                                                                                                                        Feb 15, 2018: Sol-Gel’s Phase 2 Data on TWIN to be Presented at the 2018 American Academy of Dermatology Annual Meeting

                                                                                                                                                                                                                                                          Jan 12, 2018: Ortho Dermatologics Announces U.S. FDA Filing Acceptance For IDP-121 Acne Treatment In Lotion Form

                                                                                                                                                                                                                                                            Dec 12, 2017: Clementia Initiates Pivotal Phase 3 MOVE Trial for Palovarotene in Patients with Fibrodysplasia Ossificans Progressiva

                                                                                                                                                                                                                                                              Nov 20, 2017: Preclinical study demonstrates promising treatment for rare bone disease

                                                                                                                                                                                                                                                                Nov 09, 2017: Promius Pharma Initiates Phase 3 Clinical Trials of DFD-03 for The Treatment of Acne Vulgaris

                                                                                                                                                                                                                                                                  Nov 02, 2017: Ortho Dermatologics Announces U.S. FDA Filing Acceptance For IDP-118, Novel Plaque Psoriasis Treatment

                                                                                                                                                                                                                                                                    Sep 05, 2017: Ortho Dermatologics Submits New Drug Application To The U.S. Food And Drug Administration For Psoriasis Treatment IDP-118

                                                                                                                                                                                                                                                                      Aug 31, 2017: Clementia Announces Data Presentations at Upcoming Medical Conferences in September

                                                                                                                                                                                                                                                                        Jul 20, 2017: Sol-Gel Announces Positive Phase 2 Clinical Trial Results for TWIN in Patients with Acne Vulgaris

                                                                                                                                                                                                                                                                          Jun 05, 2017: Clementia Pharmaceuticals to Host Symposium at the 8th International Conference on Children’s Bone Health

                                                                                                                                                                                                                                                                            Appendix

                                                                                                                                                                                                                                                                              Methodology

                                                                                                                                                                                                                                                                                Coverage

                                                                                                                                                                                                                                                                                  Secondary Research

                                                                                                                                                                                                                                                                                    Primary Research

                                                                                                                                                                                                                                                                                      Expert Panel Validation

                                                                                                                                                                                                                                                                                        Contact Us

                                                                                                                                                                                                                                                                                          Disclaimer

                                                                                                                                                                                                                                                                                          Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Pipeline Review, H2 2018

                                                                                                                                                                                                                                                                                          Summary

                                                                                                                                                                                                                                                                                          According to the recently published report 'Retinoic Acid Receptor Gamma - Pipeline Review, H2 2018'; Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) pipeline Target constitutes close to 21 molecules.

                                                                                                                                                                                                                                                                                          Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Retinoic acid receptor gamma (RARG) is a nuclear receptor that is encoded by the RARG gene. RARG bind as heterodimers to the target response elements in response to their ligands (all-trans or 9-cis retinoic acid) and regulate gene expression in various biological processes. In the absence or presence of hormone ligand, acts mainly as an activator of gene expression due to weak binding to co-repressors. It is required for limb bud development.

                                                                                                                                                                                                                                                                                          The report 'Retinoic Acid Receptor Gamma - Pipeline Review, H2 2018' outlays comprehensive information on the Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

                                                                                                                                                                                                                                                                                          It also reviews key players involved in Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Preclinical and Discovery stages are 1, 1, 5, 6, 7 and 1 respectively.

                                                                                                                                                                                                                                                                                          Report covers products from therapy areas Dermatology, Musculoskeletal Disorders, Immunology, Oncology, Ophthalmology, Respiratory, Gastrointestinal and Genetic Disorders which include indications Acne Vulgaris, Bronchopulmonary Dysplasia, Allergies, Autoimmune Disorders, Congenital Ichthyosis, Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva), Fibrosis, Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome), Head And Neck Cancer, Inflammatory Bowel Disease, Keratoconjunctivitis Sicca (Dry Eye), Multiple Hereditary Exostoses, Plaque Psoriasis (Psoriasis Vulgaris) and Retinopathy Of Prematurity.

                                                                                                                                                                                                                                                                                          Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

                                                                                                                                                                                                                                                                                          Scope

                                                                                                                                                                                                                                                                                          - The report provides a snapshot of the global therapeutic landscape for Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG)
                                                                                                                                                                                                                                                                                          - The report reviews Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
                                                                                                                                                                                                                                                                                          - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
                                                                                                                                                                                                                                                                                          - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
                                                                                                                                                                                                                                                                                          - The report reviews key players involved in Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics and enlists all their major and minor projects
                                                                                                                                                                                                                                                                                          - The report assesses Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
                                                                                                                                                                                                                                                                                          - The report summarizes all the dormant and discontinued pipeline projects
                                                                                                                                                                                                                                                                                          - The report reviews latest news and deals related to Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics

                                                                                                                                                                                                                                                                                          Reasons to buy

                                                                                                                                                                                                                                                                                          - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
                                                                                                                                                                                                                                                                                          - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
                                                                                                                                                                                                                                                                                          - Identify and understand the targeted therapy areas and indications for Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG)
                                                                                                                                                                                                                                                                                          - Identify the use of drugs for target identification and drug repurposing
                                                                                                                                                                                                                                                                                          - Identify potential new clients or partners in the target demographic
                                                                                                                                                                                                                                                                                          - Develop strategic initiatives by understanding the focus areas of leading companies
                                                                                                                                                                                                                                                                                          - Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
                                                                                                                                                                                                                                                                                          - Devise corrective measures for pipeline projects by understanding Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) development landscape
                                                                                                                                                                                                                                                                                          - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope




                                                                                                                                                                                                                                                                                          Summary:
                                                                                                                                                                                                                                                                                          Get latest Market Research Reports on Retinoic Acid Receptor Gamma. Industry analysis & Market Report on Retinoic Acid Receptor Gamma is a syndicated market report, published as Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Pipeline Review, H2 2018. It is complete Research Study and Industry Analysis of Retinoic Acid Receptor Gamma market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.


                                                                                                                                                                                                                                                                                          REPORT YOU MIGHT BE INTERESTED

                                                                                                                                                                                                                                                                                          Purchase this Report

                                                                                                                                                                                                                                                                                          $3,500.00
                                                                                                                                                                                                                                                                                          $7,000.00
                                                                                                                                                                                                                                                                                          $10,500.00
                                                                                                                                                                                                                                                                                          2,350.25
                                                                                                                                                                                                                                                                                          4,700.50
                                                                                                                                                                                                                                                                                          7,050.75
                                                                                                                                                                                                                                                                                          3,220.70
                                                                                                                                                                                                                                                                                          6,441.40
                                                                                                                                                                                                                                                                                          9,662.10
                                                                                                                                                                                                                                                                                          423,990.00
                                                                                                                                                                                                                                                                                          847,980.00
                                                                                                                                                                                                                                                                                          1,271,970.00
                                                                                                                                                                                                                                                                                          232,096.90
                                                                                                                                                                                                                                                                                          464,193.80
                                                                                                                                                                                                                                                                                          696,290.70
                                                                                                                                                                                                                                                                                          Credit card Logo

                                                                                                                                                                                                                                                                                          Related Reports


                                                                                                                                                                                                                                                                                          Reason to Buy

                                                                                                                                                                                                                                                                                          Request for Sample of this report